MX338017B - Formulaciones liofilizadas del factor de crecimiento de fibroblastos 18. - Google Patents

Formulaciones liofilizadas del factor de crecimiento de fibroblastos 18.

Info

Publication number
MX338017B
MX338017B MX2013014894A MX2013014894A MX338017B MX 338017 B MX338017 B MX 338017B MX 2013014894 A MX2013014894 A MX 2013014894A MX 2013014894 A MX2013014894 A MX 2013014894A MX 338017 B MX338017 B MX 338017B
Authority
MX
Mexico
Prior art keywords
freeze
fgf
formulations
dried formulations
dried
Prior art date
Application number
MX2013014894A
Other languages
English (en)
Other versions
MX2013014894A (es
Inventor
Rio Alessandra Del
Alessandra Cerreti
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338017(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MX2013014894A publication Critical patent/MX2013014894A/es
Publication of MX338017B publication Critical patent/MX338017B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al campo de las formulaciones farmacéuticas; más en particular, se refiere a formulaciones liofilizadas de compuesto de factor de crecimiento de fibroblastos 18 (FGF-18) y a métodos de producción de tales formulaciones; las formulaciones liofilizadas de acuerdo con la invención son estables después del almacenamiento durante un período apropiado; se pueden usar, después de reconstituir, para el tratamiento de trastornos de los cartílagos tales como osteoartritis o lesión de los cartílagos. Una formulación liofilizada estable, caracterizada porque comprende FGF-18, un tampón de fosfato que mantiene el pH comprendido entre 7.0 y 7.5, poloxámero 188 y sacarosa.
MX2013014894A 2011-06-17 2012-06-15 Formulaciones liofilizadas del factor de crecimiento de fibroblastos 18. MX338017B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21
PCT/EP2012/061495 WO2012172072A1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18

Publications (2)

Publication Number Publication Date
MX2013014894A MX2013014894A (es) 2014-09-01
MX338017B true MX338017B (es) 2016-03-29

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014894A MX338017B (es) 2011-06-17 2012-06-15 Formulaciones liofilizadas del factor de crecimiento de fibroblastos 18.

Country Status (31)

Country Link
US (2) US9326944B2 (es)
EP (2) EP3056211A1 (es)
JP (1) JP5981538B2 (es)
KR (1) KR102019520B1 (es)
CN (2) CN103619347A (es)
AR (1) AR086956A1 (es)
AU (1) AU2012268987B2 (es)
BR (1) BR112013032400B1 (es)
CA (1) CA2836667C (es)
CL (1) CL2013003618A1 (es)
CO (1) CO6940377A2 (es)
CY (1) CY1117933T1 (es)
DK (1) DK2720710T3 (es)
EA (1) EA024937B1 (es)
EC (1) ECSP14013157A (es)
ES (1) ES2575732T3 (es)
HR (1) HRP20160566T1 (es)
HU (1) HUE028355T2 (es)
IL (1) IL229977A (es)
MX (1) MX338017B (es)
MY (1) MY170630A (es)
PE (1) PE20141265A1 (es)
PL (1) PL2720710T3 (es)
PT (1) PT2720710E (es)
RS (1) RS54875B1 (es)
SG (1) SG195021A1 (es)
SI (1) SI2720710T1 (es)
TW (1) TWI527590B (es)
UA (1) UA113174C2 (es)
WO (1) WO2012172072A1 (es)
ZA (1) ZA201308698B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
WO2015097236A2 (en) 2013-12-24 2015-07-02 Ares Trading S.A Fgf-18 formulation in alginate/collagen hydrogels
RU2745453C2 (ru) * 2015-08-13 2021-03-25 Мерк Патент Гмбх Комбинированная композиция, содержащая соединение fgf-18
TWI813597B (zh) * 2017-11-10 2023-09-01 瑞士商諾華公司 用於關節內施用之延長釋放調配物
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
IL129379A (en) * 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
WO2001039788A2 (en) 1999-12-02 2001-06-07 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
EP1814573B1 (en) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2592261C (en) * 2004-12-10 2015-11-24 Zymogenetics Inc. Fgf18 production in prokaryotic hosts
CA2634547C (en) * 2005-12-20 2016-10-11 Bristol-Myers Squibb Company Stable ctla4 formulation for subcutaneous administration
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
WO2008023063A2 (en) 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
KR20140012199A (ko) * 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
SI2068909T1 (sl) * 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
PT2234600E (pt) * 2007-12-21 2014-09-25 Hoffmann La Roche Formulação de anticorpos
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
DK2720710T3 (en) 2016-06-27
BR112013032400A2 (pt) 2016-11-22
RS54875B1 (sr) 2016-10-31
CN103619347A (zh) 2014-03-05
EP3056211A1 (en) 2016-08-17
TW201302217A (zh) 2013-01-16
NZ617992A (en) 2015-09-25
EP2720710A1 (en) 2014-04-23
KR20140041600A (ko) 2014-04-04
ZA201308698B (en) 2016-02-24
IL229977A (en) 2017-01-31
AR086956A1 (es) 2014-02-05
CL2013003618A1 (es) 2014-07-04
EA024937B1 (ru) 2016-11-30
US20160228374A1 (en) 2016-08-11
AU2012268987B2 (en) 2016-09-08
ECSP14013157A (es) 2014-02-28
ES2575732T3 (es) 2016-06-30
US9326944B2 (en) 2016-05-03
SG195021A1 (en) 2013-12-30
JP5981538B2 (ja) 2016-08-31
JP2014522807A (ja) 2014-09-08
CO6940377A2 (es) 2014-05-09
PE20141265A1 (es) 2014-09-29
EP2720710B1 (en) 2016-03-23
EA201490032A1 (ru) 2014-05-30
SI2720710T1 (sl) 2016-07-29
CY1117933T1 (el) 2017-05-17
US20140121162A1 (en) 2014-05-01
CA2836667C (en) 2020-01-14
HUE028355T2 (en) 2016-12-28
BR112013032400B1 (pt) 2021-07-20
CN107715104A (zh) 2018-02-23
KR102019520B1 (ko) 2019-11-04
MX2013014894A (es) 2014-09-01
HRP20160566T1 (hr) 2016-06-17
PT2720710E (pt) 2016-06-17
MY170630A (en) 2019-08-21
CA2836667A1 (en) 2012-12-20
WO2012172072A1 (en) 2012-12-20
PL2720710T3 (pl) 2016-09-30
TWI527590B (zh) 2016-04-01
UA113174C2 (xx) 2016-12-26

Similar Documents

Publication Publication Date Title
MY170630A (en) Freeze-dried formulations of fgf-18
AU2018236800B2 (en) DNA-PK inhibitors
AU2018256635A1 (en) Methods for treating anemia
MX2016008442A (es) Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
UA114907C2 (uk) Гетероциклільні сполуки як інгібітори mek
UA115983C2 (uk) Інгібітори днк-пк
UA105290C2 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
MY161088A (en) Agonists of gpr40
CA2818187C (en) Bromodomain inhibitors and uses thereof
IN2014DN10386A (es)
WO2012174487A8 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
EA201390010A1 (ru) Замещенные триазолопиридины
WO2011025286A3 (ko) 리포테이코익산 유래 당지질 및 이를 포함하는 조성물
PH12016502447A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2560633A4 (en) INTRAVENOUS COMPOSITIONS OF OMEGA-3 FATTY ACIDS AND METHOD OF USE
MX2013011421A (es) Derivados de pirazolo-pirimidina.
WO2013123249A3 (en) Formulations and methods for treating ear conditions
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
NZ723169A (en) Fgf-18 in graft transplantation and tissue engineering procedures
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX368946B (es) Implante que contiene factor de crecimiento de fibroblastos 18.

Legal Events

Date Code Title Description
FG Grant or registration